Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?
AstraZeneca is withdrawing the drug Zoladex from the Australian market, impacting thousands of women who rely on it for breast cancer and endometriosis treatment. Patients are concerned about the lack of alternatives and the potential for treatment gaps.
Why it matters
Demonstrates the impact of pharmaceutical supply chain decisions on public health and patient access to critical care.
Manufactured by AstraZeneca, Zoladex provides pain relief for women with endometriosis and is a treatment for breast cancer. Photograph: Olena Malik/Getty Images View image in fullscreen Manufactured by AstraZeneca, Zoladex provides pain relief for women with endometriosis and is a treatment for breast cancer. Photograph: Olena Malik/Getty Images Health Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected? The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment
Focuses on patient impact and medical facts, though highlights a systemic health concern.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in